Welcome to our dedicated page for Scynexis news (Ticker: SCYX), a resource for investors and traders seeking the latest updates and insights on Scynexis stock.
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company developing antifungal medicines based on its proprietary triterpenoid antifungal platform known as "fungerps." News about SCYNEXIS frequently centers on clinical data, regulatory interactions, collaborations, and its exclusive license agreement with GSK for ibrexafungerp, the active ingredient in the FDA-approved product BREXAFEMME for vulvovaginal candidiasis and reduction in the incidence of recurrent VVC.
On this page, readers can follow company announcements related to the development of next-generation fungerps, including SCY-247, which SCYNEXIS describes as a second-generation triterpenoid antifungal under clinical and preclinical evaluation for invasive fungal infections. Recent updates have highlighted positive Phase 1 single and multiple ascending dose results, preclinical data presented at scientific congresses, and plans for additional studies using both oral and intravenous formulations.
SCYNEXIS news also covers key events in its collaboration with GSK, such as the transfer of the BREXAFEMME New Drug Application, resolution of disagreements regarding the Phase 3 MARIO study in invasive candidiasis, and associated milestone or other payments. Regulatory and listing developments, including Nasdaq minimum bid price notices and extensions to regain compliance, are disclosed through company press releases and SEC filings.
Investors, clinicians, and researchers can use this news feed to review updates on clinical trial progress, antifungal data presentations, license agreement developments, and corporate milestones. Regularly checking this page helps users track how SCYNEXIS advances its fungerp platform, manages its partnership with GSK, and responds to regulatory and market requirements.
Poxel sold clinical-stage AMPK activator PXL770 (to be renamed SCY-770) to Scynexis (NASDAQ: SCYX) for total consideration of up to $196 million, including an $8 million upfront payment and up to $188 million in milestone payments. PXL770 holds FDA orphan drug designation and patent protection through at least 2041. A Phase 2 ADPKD proof-of-concept study is expected to start in Q4 2026 with a first efficacy readout in H2 2027. IPF will receive 75% of proceeds to repay debt, with limited amounts retained for Poxel liquidity.
SCYNEXIS (NASDAQ: SCYX) entered a private placement expected to close on or about April 1, 2026, generating approximately $40.0 million upfront and up to $52.2 million more if Common Warrants are fully exercised, subject to stockholder approval.
The company will issue 34,750,000 common shares, 8,750,000 pre-funded warrants and accompanying Common Warrants for an aggregate of 43,500,000 warrants; combined prices were $0.92 and $0.9199. The financing extends cash runway into mid-2029 and includes institutional investors and CEO participation.
SCYNEXIS (NASDAQ: SCYX) completed a transformative asset acquisition of PXL-770 (now SCY-770), a clinical-stage oral, selective direct AMPK activator for autosomal dominant polycystic kidney disease (ADPKD). The company will pursue a Phase 2 proof-of-concept study beginning in Q4 2026, with an early efficacy readout expected in H2 2027. SCY-770 has U.S. FDA Orphan Drug Designation. Transaction terms include an $8 million upfront payment plus up to $8 million in development milestones and up to $180 million in commercial milestones.
SCYNEXIS (NASDAQ: SCYX) reported full-year 2025 results and a corporate update highlighting a $24.8M one-time payment from GSK, year-end cash, cash equivalents and investments of $56.3M and a cash runway of more than two years. The company advanced SCY-247, began IV dosing (topline data H2 2026), plans an expanded access program H1 2026, and received QIDP and Fast Track designations.
Full-year 2025 revenue totaled $20.6M versus $3.7M in 2024; R&D expense fell 15.6% to $22.3M.
SCYNEXIS (NASDAQ: SCYX) announced dosing of first participants in a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of intravenous SCY-247 for invasive candidiasis and prophylaxis against invasive fungal disease. FDA QIDP and Fast Track designations were previously granted. Results from the IV trial are expected in 2026. The company noted positive SAD/MAD oral SCY-247 data in September 2025 showing target exposures at lower doses and is exploring non-dilutive funding to support the program.
SCYNEXIS (NASDAQ: SCYX) announced presentations on its second‑generation fungerp, SCY-247, at the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI), Jan 28–30, 2026, in Las Vegas.
The company said SCY-247 showed potent in vitro and in vivo antifungal activity, a favorable safety profile, and supportive pharmacokinetics in clinical investigations to date. Oral presentation: Jan 29, 9:00–10:30am; poster: Jan 30. Materials will be posted in the company’s Publications and Presentations section after the meeting.
SCYNEXIS (NASDAQ: SCYX) announced that the U.S. FDA granted QIDP and Fast Track designations for its second‑generation triterpenoid antifungal, SCY-247. The company noted QIDP will provide at least 10 years of post‑approval market exclusivity and Fast Track may enable more frequent FDA interaction, rolling review, and eligibility for accelerated approval or priority review. SCYNEXIS plans to initiate a Phase 1 IV study and a Phase 2 oral study in invasive candidiasis in 2026, and aims to release oral proof‑of‑concept data the same year. SCY-247 has shown preclinical activity against multi‑drug resistant fungi including Candida auris and azole‑resistant Aspergillus.
SCYNEXIS (NASDAQ: SCYX) received a 180-calendar-day extension from Nasdaq to regain compliance with the minimum bid price rule, extending the cure period to June 15, 2026.
Nasdaq confirmed SCYNEXIS meets other continued listing criteria and the company said it may use a reverse stock split if needed. Management also confirmed plans to complete a Phase 1 IV study and seek proof-of-concept Phase 2 oral data for investigational antifungal SCY-247 in invasive candidiasis, while maintaining commitments to regain full Nasdaq compliance.
SCYNEXIS (NASDAQ: SCYX) completed transfer of the BREXAFEMME (ibrexafungerp) NDA to GSK on November 19, 2025. GSK can now initiate regulatory interactions with the FDA to discuss a U.S. relaunch for vulvovaginal candidiasis (VVC) and refractory VVC (rVVC). Following a relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones plus royalties, which are payable net of amounts due to Merck and expected in the low- to mid-single digit percentage range. The company describes these payments as a potential source of future non-dilutive capital.
SCYNEXIS (NASDAQ: SCYX) announced it is a collaborator in a new Center of Excellence in Translational Research jointly led by Hackensack Meridian CDI and Johns Hopkins Bloomberg School of Public Health that received a federal five-year grant from NIAID.
The CETR expects to receive about $7 million annually, contingent on availability of funds, to support five projects including a novel series of SCYNEXIS’ proprietary triterpenoid antifungals (next‑generation fungerps) aimed to advance selected preclinical candidates toward IND readiness for resistant fungal infections.